SCHEMBL2483164

SCHEMBL2483164

Nc1ccc2nc(C(=O)Nc3ccccc3)cn2c1Cl

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 7/20 0.54
NPC1 O15118 5/20 0.54
ADORA2A P29274 4/20 0.53
ADORA1 P30542 4/20 0.53
CYP2C9 P11712 1/20 0.48
NR4A2 P43354 1/20 0.48
POLB P06746 1/20 0.48
SMN1; SMN2 Q16637 5/20 0.45
CNR1 P21554 3/20 0.43
NFKB1 P19838 1/20 0.43
NFKB2 Q00653 1/20 0.43
RELA Q04206 1/20 0.43
KMT2A Q03164 2/20 0.42
MAPT P10636 1/20 0.41
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
GAA P10253 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2489707 0.86 RAB9A (0.53) RAB9ANPC1ADORA2AADORA1CYP2C9
SCHEMBL2483778 0.81 ADORA2A (0.50) RAB9ANPC1ADORA2AADORA1CYP2C9
SCHEMBL3367951 0.77 RAB9A (0.56) RAB9ANPC1ADORA2AADORA1CYP2C9
SCHEMBL3367652 0.76 RAB9A (0.51) RAB9ANPC1ADORA2AADORA1CYP2C9
SCHEMBL3367434 0.76 RAB9A (0.65) RAB9ANPC1ADORA2AADORA1CYP2C9
SCHEMBL2485519 0.76 RAB9A (0.68) RAB9ANPC1ADORA2AADORA1CYP2C9
SCHEMBL3366002 0.75 RAB9A (0.53) RAB9ANPC1ADORA2AADORA1CYP2C9
SCHEMBL3367638 0.75 RAB9A (0.53) RAB9ANPC1ADORA2AADORA1CYP2C9
SCHEMBL3367654 0.74 RAB9A (0.70) RAB9ANPC1CYP2C9NR4A2POLB
SCHEMBL3367363 0.74 NPC1 (0.65) RAB9ANPC1CYP2C9NR4A2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2225245-B1 N-phenyl-imidazo(1,2-a)pyridine-2-carboxamide compounds, preparation thereof and therapeutic application thereof SANOFI SA (FR) 2011-10-19 EP claimed
US-20100317620-A1 N-PHENYLIMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE COMPOUNDS, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2010-12-16 US claimed
EP-2225245-B1 N-phenyl-imidazo(1,2-a)pyridine-2-carboxamide compounds, preparation thereof and therapeutic application thereof SANOFI SA (FR) 2011-10-19 EP disclosed
US-20100317620-A1 N-PHENYLIMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE COMPOUNDS, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2010-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317620-A1 N-PHENYLIMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE COMPOUNDS, PREPARATION AND THERAPEUTIC USE THEREOF GLS, REN, XDH RAB9A 1438/4885NPC1 595/4885ADORA2A 237/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.